- Opsens has the opportunity to become a multi-product company from a single-product company with rising relevance in the medical community and GPOs.
- If successful, Opsens can grow revenues to ~CAD$145 million over the next few years from the current revenues of ~CAD$30 million.
- This revenue growth will be driven by consistent introduction of innovative products and new partnerships with distributors.
- The successful launch of TAVR product line in 2022 will be a game-changer as revenue and profitability will rise dramatically.
- Experienced investors should add Opsens to their watchlist or even consider initiating a position before the successful launch of TAVR.
For further details see:
Opsens: The Making Of A Diversified Medical Technology Company